Charles Schwab Investment Management Inc. Increases Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Charles Schwab Investment Management Inc. increased its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 322,576 shares of the biotechnology company’s stock after acquiring an additional 8,311 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.57% of Astria Therapeutics worth $2,884,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Astria Therapeutics during the 3rd quarter valued at $613,000. FMR LLC increased its stake in Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after acquiring an additional 1,767,714 shares during the last quarter. Barclays PLC raised its holdings in shares of Astria Therapeutics by 70.5% in the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock worth $1,020,000 after purchasing an additional 38,321 shares during the period. Vestal Point Capital LP lifted its stake in shares of Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Astria Therapeutics during the 3rd quarter worth about $228,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. JMP Securities began coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target on the stock. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Wedbush restated an “outperform” rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $26.60.

Astria Therapeutics Trading Down 0.8 %

NASDAQ ATXS opened at $6.06 on Friday. The stock has a market cap of $341.99 million, a P/E ratio of -2.90 and a beta of 0.69. The company’s fifty day simple moving average is $6.84 and its 200-day simple moving average is $9.19. Astria Therapeutics, Inc. has a 52 week low of $5.73 and a 52 week high of $14.79.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. On average, research analysts expect that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.